Welcome to our dedicated page for Biovie news (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on Biovie stock.
BioVie Inc. (BIVI) is a clinical-stage biotechnology company pioneering novel therapies for chronic liver disease complications and neurodegenerative disorders. This page serves as the definitive source for all official company updates, including clinical trial progress, regulatory milestones, and strategic developments.
Access real-time announcements about BIV201 for liver ascites management and bezisterim for Alzheimer’s/Parkinson’s research. Stay informed on orphan drug designations, partnership agreements, and financial disclosures that shape BioVie’s innovative pipeline.
All content is rigorously curated to provide investors and researchers with compliant, actionable insights. Bookmark this hub for authoritative updates on therapies addressing critical unmet medical needs through advanced clinical research.
Rhea-AI Summary
RedChip Companies will air interviews with bioAffinity Technologies, Inc. (BIAF) and BioVie, Inc. (BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV. BioAffinity Technologies is an emerging player in early-stage cancer diagnosis and treatment, with a focus on lung cancer detection. The company's flagship product, CyPath® Lung, has shown high sensitivity, specificity, and accuracy in detecting early-stage lung cancer. The company also holds extensive U.S. and international patents and has strong insider ownership at 39%. BioVie, Inc. is a clinical-stage company developing therapies for Alzheimer's, Parkinson's, refractory ascites, and HRS-AKI. The company recently reported positive trending data from a Phase 3 trial in Alzheimer's and has plans to launch Phase 3 trials in 2024 for Alzheimer's, Parkinson's, and Ascites.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
-
Rhea-AI Summary
RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET). Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType multi-risk test covering various diseases, with a global market expected to reach $4.6 billion by 2025. BioVie is a clinical-stage company developing transformative therapies for Alzheimer's, Parkinson's, and liver diseases, with positive trending data from a Phase 3 trial in AD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
-
Rhea-AI Summary
RedChip Companies will air interviews with Rail Vision (NASDAQ:RVSN) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show on Bloomberg TV this Saturday, December 23, at 7 p.m. Eastern Time (ET). Rail Vision is a company at the forefront of an evolution in train safety, providing AI-based detection systems for obstacle identification on and near tracks. Knorr Bremse, a key strategic investor, has invested $25M across two investment cycles. BioVie is a clinical-stage company developing transformative therapies for neurodegeneration and liver disease, with positive trending data from a Phase 3 trial in Alzheimer's and Parkinson's. The company plans to launch Phase 3 trials in 2024 and has multiple other efforts underway that may create additional catalysts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
Rhea-AI Summary
BioVie Inc. (NASDAQ: BIVI) announced positive analysis of unblinded, topline efficacy data from its Phase 3 clinical trial of NE3107 in the treatment of mild to moderate Alzheimer’s Disease. The trial showed NE3107’s treatment advantage over placebo to potentially be equal to or greater than data reported from clinical trials for the approved medications for AD without the associated safety concerns. The trial started during the COVID-19 pandemic, enrolling 439 patients through 39 sites. The trial identified significant deviations from protocol and Good Clinical Practice (GCP) violations at 15 sites, leading to exclusions and referral to the U.S. Food and Drug Administration (FDA) Office of Scientific Investigations (OSI) for further action. After exclusions, 81 patients remained in the Modified Intent to Treat (MITT) population, 57 of whom were in the Per-Protocol population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60.72%
Tags
-
Rhea-AI Summary
BioVie Inc. (NASDAQ: BIVI) announces positive clinical safety data from Phase 2b study of BIV201, a continuous infusion of terlipressin, in combination with standard of care for patients with refractory ascites due to cirrhosis. The data supports the acceleration of BIV201 into Phase 3 trials, with a commitment to commence in Q2 2024. The results show favorable safety profile and well-tolerated combination with standard of care, encouraging further development and investigation in confirmatory trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.57%
Tags
-
Rhea-AI Summary
BioVie Inc. announced the participation of its management team in the Truist Securities BioPharma Symposium to be held in New York on November 8-9, 2023. The symposium will include a panel presentation on 'Exploring Late-Stage New Modalities in Alzheimer's Disease' and one-on-one investor meetings. For more information, contact Truist Securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
Rhea-AI Summary
BioVie Inc. announced that its management will host a conference call and webcast on November 1, 2023, to review recent data on NE3017 presented at the CTAD conference. The call will be led by BioVie's President and CEO Cuong Do, Chief Medical Officer Dr. Joseph Palumbo, and Dr. Steven Arnold of Harvard Medical School.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.32%
Tags
-
Rhea-AI Summary
BioVie to present clinical safety data on BIV201 at AASLD conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
-
Rhea-AI Summary
BioVie presents blinded data on cognitive, biomarker, and imaging findings from Phase 3 trial of NE3107 in Alzheimer's Disease at CTAD. Statistically significant population changes observed in cognitive and functional assessments. Reduction in amyloid burden observed. Increases in insulin and beta cell function without hypoglycemia. Increased FDG-PET SUVRs suggestive of reduced amyloid burden. Unblinded, topline data expected in late November or early December.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.97%
Tags
Rhea-AI Summary
BioVie to present blinded data on Phase 3 clinical trial of NE3107 for Alzheimer's Disease at CTAD conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.1%
Tags
Biovie Inc
Nasdaq:BIVI
BIVI Rankings
BIVI Stock Data
15.51M
15.97M
13.09%
4.27%
8.88%
Biotechnology
Pharmaceutical Preparations
United States
CARSON CITY